SENIOR LEADERSHIP Since the previous review, there has been significant recruitment and promotion of key individuals to senior leadership positions to expand the Cancer Center leadership from five positions (Director and four Associate Directors) to eight. The Center Director, Theodore Krontiris, MD, PhD, in his capacity as Center Director and as Executive Vice President for Medical and Scientific Affairs of City of Hope, is the chief means by which all organizational entities and inherent capabilities are integrated in the research of the Cancer Center. As EVPMSA, he oversees the derivation and renewal of the Institutional strategic plan. Through his collaboration with, and oversight of, the COH Beckman Research Institute (BRI) Director and the COH National Medical Center (NMC) Chief Medical Officer, he assures that faculty hiring in the BRI and NMC, respectively, conforms to the strategic plan and is consonant with needs of the Cancer Center Programs?for expanding their interdisciplinary research activities, as well as addressing peer-review and external advisors'recommendations about the state of the Center. The Deputy Director, Richard Jove, PhD, recruited from H. Lee Moffitt Cancer Center, has substantial experience in leading translational research programs. He oversees the implementation of the overall Center strategy and has scientific oversight of Shared Resources. The AD for Administration, Michael Benedict, PharmD, oversees all office operations and CCSG management, and has administrative oversight of Shared Resources. Robert Figlin, MD, AD for Clinical Research, was recently recruited from UCLA. He oversees all clinical cancer activities and the coordination of all cancer clinical trials. Yun Yen, MD, PhD, is the AD for Translational Research, a new leadership position since the previous review. He is responsible for integrating correlative laboratory studies into clinical trials. In addition, Drs. Yen and Figlin co-chair the Task Force for Cancer Center Disease Program Development (see Essential Characteristics), which includes the Deputy Director and the other ADs as members. Smita Bhatia, MD, a national leader in cancer survivorship studies, was promoted to AD for Population Research and is responsible for developing research directions in cancer prevention and control. John Rossi, PhD, is a longtime leader in RNA biology and continues to foster successful interdisciplinary collaborations within the Cancer Center membership as part of his role as AD for Basic Research. Joyce Niland, PhD, with her outstanding experience in medical informatics, was appointed AD for Information Sciences, a new AD position concomitant with the increasing role of informatics in Cancer Center operations. In addition to the qualifications and roles of each of the Senior Leadership positions described on the following pages, many of these Cancer Center leaders are Division Chairs or Department Directors within BRI or NMC.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
City of Hope/Beckman Research Institute
United States
Zip Code
Gu, Ying; Zhang, Jiawei; Ma, Xiaoxiao et al. (2017) Stabilization of the c-Myc Protein by CAMKII? Promotes T Cell Lymphoma. Cancer Cell 32:115-128.e7
Cao, Pengpeng; Mooney, Rachael; Tirughana, Revathiswari et al. (2017) Intraperitoneal Administration of Neural Stem Cell-Nanoparticle Conjugates Targets Chemotherapy to Ovarian Tumors. Bioconjug Chem 28:1767-1776
Mohanty, Suchismita; Mohanty, Atish; Sandoval, Natalie et al. (2017) Cyclin D1 depletion induces DNA damage in mantle cell lymphoma lines. Leuk Lymphoma 58:676-688
Wittenberg, Elaine; Ferrell, Betty; Koczywas, Marianna et al. (2017) Pilot Study of a Communication Coaching Telephone Intervention for Lung Cancer Caregivers. Cancer Nurs :
Yuan, Yuan; Vora, Nilesh; Sun, Can-Lan et al. (2017) Association of Pre-Chemotherapy Peripheral Blood Pro-Inflammatory and Coagulation Factors with Physical Function in Women with Breast Cancer. Oncologist 22:1189-1196
Deng, Ruishu; Hurtz, Christian; Song, Qingxiao et al. (2017) Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease. Nat Commun 8:978
He, Zhiheng; Ma, Jian; Wang, Ruiqing et al. (2017) A two-amino-acid substitution in the transcription factor ROR?t disrupts its function in TH17 differentiation but not in thymocyte development. Nat Immunol 18:1128-1138
Kortylewski, Marcin; Moreira, Dayson (2017) Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities. Cancer Immunol Immunother 66:979-988
Somlo, George; Frankel, Paul H; Arun, Banu K et al. (2017) Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res 23:4066-4076
Slavin, Thomas P; Neuhausen, Susan L; Nehoray, Bita et al. (2017) The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes. Fam Cancer :

Showing the most recent 10 out of 1277 publications